Singapore-based Credence Genomics is advancing its nanopore sequencing-based microbial testing technologies targeting bacterial, fungal, and viral pathogens. Its assays, including Bactfast and Fungifast, have secured EU IVDR Class A registration, and regulatory approval efforts continue for its viral panel Virfast. The company has partnered with Oxford Nanopore Technologies to leverage the MinIon sequencing platform, enabling rapid, accurate pathogen identification and antimicrobial susceptibility testing. Credence targets markets beyond Southeast Asia, including the US and EU, emphasizing cost-effective, precise infectious disease diagnostics for global health challenges.